AnaptysBio Inc. ANAB
$59.87
▲ +3.37% 24H
About
AnaptysBio Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. It advances antibody-based drug candidates that modulate immune pathways, including rosnilimab, a PD-1 agonist and pathogenic T cell depleter studied in rheumatoid…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees104
TickerANAB
Statistics
Market Cap$1.74B
Revenue (TTM)$234.6M
Net Income-$13.2M
Net Margin-5.6%
EPS$-0.46
P/E-122.11
P/S6.79
P/B123.55
EV/EBITDA36.45
ROE-114.6%
Dividend Yield—
Price$59.87
Data: Twelve Data · Revenue = mcap / P/S